The global osteoporosis drugs market size was valued at USD 14.90 billion in 2024 and is projected to reach USD 15.39 billion ...

Osteoporosis, thin weak bones, is common in post-menopausal women and older men. While not fatal, it is a major risk for fractures and can severely impact your quality of life.

Because certain antiepileptic medications contribute to vitamin ... are themselves risk factors for osteoporosis. [91] In addition, TCAs are frequently used for indications other than depression ...

A research team co-led by scientists at the University of Arizona College of Medicine—Tucson found that an osteoporosis drug might counter a rare genetic mutation underlying a type of heart disease.

"Drug repurposing using FDA-approved drugs is a fast track to bring these therapies to patients." The heart's pump is powered by a "motor" made up of many constituent parts - proteins.

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

The FDA has accepted Amneal’s biologics licensing application for two biosimilars referencing Prolia and Xgeva.

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...

Celltrion has received permission from the Food and Drug Administration for Stoboclo (CT-P41, denosumab-bmwo) and Osenvelt ...

The elderly population is at risk for polypharmacy and, therefore, also at risk for drug-induced osteoporosis (DIOP). Epidemiologic studies provide valuable information about medications that may ...